Global prevalence of hemophilia A reaches 13.4 cases per 100,000 males. Over one million people remain undiagnosed worldwide according to federation data. These figures on incidence, clinical features, and treatment outcomes expose sharp regional differences in detection and care.
Key Takeaways
- Severe bleeding in hemophilia manifests as hemarthrosis in 80% of untreated cases
- The global prevalence of Hemophilia A is approximately 13.4 cases per 100,000 males, with variations by region due to underdiagnosis in developing countries
- Hemophilia A is caused by mutations in the F8 gene on the X chromosome at Xq28
- Life expectancy with modern treatment reaches 70+ years, up from 20 pre-1970
- Prophylactic factor replacement started at 1-2 years reduces bleeds by 90%
Hemophilia affects thousands worldwide, and timely care can greatly improve outcomes and quality of life.
Related reading
01 · Category
Clinical Features28 stats
01
Severe bleeding in hemophilia manifests as hemarthrosis in 80% of untreated cases
02
Spontaneous joint bleeds occur in severe hemophilia (<1% factor) at frequency of 15-20/year untreated
03
Diagnosis often delayed until 1-2 years of age when toddler mobility starts
04
Prolonged aPTT with normal PT and platelets is hallmark lab finding in 95% cases
05
Intracranial hemorrhage risk is 5% in neonates with severe hemophilia
06
Muscle hematomas present in 50% of severe cases annually without prophylaxis
07
Factor VIII levels <1% define severe hemophilia with spontaneous bleeds
08
Mucocutaneous bleeding more common in mild hemophilia (factor 5-40%)
09
Pseudotumors from chronic hematomas occur in 1-2% untreated patients
10
Diagnosis confirmed by one-stage clotting assay in 98% accuracy
11
Excessive bruising noted in 90% of carrier females with low factor levels
12
Post-traumatic bleeding after circumcision in 2-5% undiagnosed males
13
Hematuria occurs in 20-30% lifetime risk for severe hemophilia
14
Genetic testing recommended if family history absent in 30% sporadic cases
15
Joint arthropathy develops in 70% by age 30 without prophylaxis
16
Epistaxis in 15% of pediatric hemophilia patients annually
17
Bethesda assay quantifies inhibitors in 30% severe Hemophilia A patients
18
Oral bleeding post-dental extraction without treatment in 80%
19
Retroperitoneal bleeds mimic acute abdomen in 5% emergency presentations
20
MRI detects early synovitis in 60% prophylaxed joints
21
Neonatal screening via cord blood identifies 100% severe cases
22
Fatigue and pallor from chronic anemia in 40% untreated adults
23
Compartment syndrome from calf bleeds in 10% trauma cases
24
Menorrhagia in 30-50% carrier females
25
Ultrasound scores joint damage in 85% correlation with clinical
26
Inhibitor development symptoms mimic worsening hemophilia in 25%
27
GI bleeding from angiodysplasia in 5-10% elderly patients
28
Thrombin generation assays predict bleed risk better than factor levels (75%)
Interpretation
Clinical Features Interpretation
A toddler's first wobbly steps should be a triumph, but for those with severe hemophilia, this milestone often ushers in a lifetime where 20 spontaneous joint bleeds a year can culminate in a 70% chance of crippled joints by age 30, proving that a single missing protein can turn the body's own plumbing into a relentless, internal vandal.
02 · Category
Epidemiology30 stats
01
The global prevalence of Hemophilia A is approximately 13.4 cases per 100,000 males, with variations by region due to underdiagnosis in developing countries
02
In the United States, about 20,000 people live with hemophilia, with Hemophilia A accounting for 80% of cases
03
The incidence of severe Hemophilia A is 1 in 5,000 to 10,000 male births worldwide
04
Hemophilia B has an incidence of 1 in 25,000 to 30,000 male births globally
05
In Europe, the prevalence of Hemophilia A is 11.3 per 100,000 males, lower than global estimates due to better registries
06
Acquired hemophilia affects 1.5 per million people annually, mostly in elderly or postpartum women
07
In India, underreporting leads to an estimated prevalence of Hemophilia A at 1 in 20,000 males
08
The World Federation of Hemophilia reports over 1 million people worldwide potentially undiagnosed with hemophilia
09
In the US, 400 babies are born annually with severe hemophilia
10
Hemophilia carrier females have a prevalence of 1 in 2,500 to 5,000 females
11
In Latin America, Hemophilia A prevalence is 7.4 per 100,000 males
12
Australia reports 2,500 registered hemophilia patients, with 70% having Hemophilia A
13
In Africa, diagnosis rates are as low as 10% of true prevalence, affecting ~50,000 undiagnosed
14
Canada has a prevalence of 20.3 per 100,000 males for all hemophilia types
15
In China, estimated 100,000 hemophilia patients, but only 20,000 diagnosed
16
Hemophilia A severe form comprises 45-52% of all hemophilia cases globally
17
Incidence of Hemophilia C (factor XI deficiency) is 1 in 100,000, higher in Ashkenazi Jews at 8%
18
UK prevalence for Hemophilia A is 14.8 per 100,000 males
19
Global male-to-female ratio for hemophilia is nearly 1000:1 for inherited forms
20
In the Middle East, prevalence is 10.4 per 100,000 males
21
US hemophilia population is 80% white, 12% Black, 8% Hispanic
22
Annual global incidence of new hemophilia diagnoses is ~30,000
23
In Brazil, 12,000 registered patients, 85% Hemophilia A
24
Russia estimates 15,000 hemophilia patients, 60% undiagnosed
25
Japan has prevalence of 5.5 per 100,000 males
26
In Southeast Asia, carrier detection rate is <10%
27
Global hemophilia registry covers 50% of cases in high-income countries
28
Italy reports 8,500 hemophilia patients, prevalence 15 per 100,000 males
29
In South Africa, only 500 diagnosed out of estimated 4,000
30
Worldwide, 3 million carriers of hemophilia genes exist
Interpretation
Epidemiology Interpretation
This data paints a stark global picture: while precise needles of diagnosis can be found in developed countries, vast swaths of the world remain a haystack of undiagnosed patients, skewing statistics and hiding the true human scale of this disorder.
03 · Category
Genetics30 stats
01
Hemophilia A is caused by mutations in the F8 gene on the X chromosome at Xq28
02
Over 2,000 unique mutations identified in F8 gene for Hemophilia A
03
Inversions in intron 22 of F8 account for 45% of severe Hemophilia A cases
04
Hemophilia B results from F9 gene mutations on Xq27.1-27.2
05
Missense mutations in F9 cause 40% of Hemophilia B cases
06
De novo mutations occur in 30% of Hemophilia A cases with no family history
07
Carrier females have 50% chance of passing X-linked hemophilia to sons
08
Skewed X-inactivation in carriers can lead to symptomatic hemophilia in 10-20% females
09
Large deletions in F8 gene cause 5% of severe Hemophilia A
10
CRM-negative Hemophilia A (no factor VIII protein) is 20-30% of cases due to nonsense mutations
11
Hemophilia B Leyden features reversible phenotype due to promoter mutation in F9
12
Genetic counseling identifies carriers via linkage analysis with 99% accuracy
13
CRISPR-Cas9 editing corrects F8 inversions in 70% of iPS cells from patients
14
Over 1,100 F9 mutations cataloged, 70% point mutations
15
Gonadal mosaicism explains 15% of sporadic Hemophilia A cases
16
Autosomal recessive forms like parahemophilia (F5 deficiency) mimic but distinct from X-linked
17
Haplotype analysis shows founder effects in 20% Ashkenazi Hemophilia B mutations
18
RNA splicing mutations account for 10-15% F8 defects
19
Prenatal diagnosis via CVS detects hemophilia with 99.9% accuracy for known mutations
20
Frameshift mutations predominate in severe Hemophilia B (25%)
21
AAV gene therapy trials restore F8 expression in 80% of Hemophilia A patients
22
CpG dinucleotide mutations are 12 times more common in F9 due to methylation
23
Female hemophilia from Turner syndrome (XO) occurs in 1% of cases
24
Next-gen sequencing detects 95% of novel F8 mutations
25
Promoter mutations cause 2-5% Hemophilia B cases
26
Whole gene deletions in F8: 3-5% severe cases
27
X-chromosome inactivation patterns predict bleeding risk in carriers (85% correlation)
28
Hemophilia A database (ECHM) logs 3,000+ mutations
29
Poly(A) signal mutations in F8 rare but cause mild disease
30
Genetic modifiers influence 20-30% factor level variability in carriers
Interpretation
Genetics Interpretation
It is a genetic tightrope walk, where a single misstep on the X chromosome can cascade through generations, yet our scientific map of its twists and turns is now precise enough to both predict the path and, increasingly, repair the rope itself.
More related reading
04 · Category
Outcomes and Complications29 stats
01
Life expectancy with modern treatment reaches 70+ years, up from 20 pre-1970
02
Prophylaxis reduces arthropathy by 80%, but HIV/HCV co-infection worsens 50%
03
Inhibitor patients have 2-5x higher bleed rates despite bypassing
04
Joint replacement needed in 15% patients by age 40 on prophylaxis
05
HIV transmission pre-1985 screening affected 50% US hemophiliacs
06
HCV cirrhosis in 20% pre-1990s plasma-derived users
07
Pseudotumor malignancy risk 5% chronic cases
08
Cardiac disease now leading cause of death post-HIV era (30%)
09
Quality of life scores (HAEM-A-QoL) improve 40% on prophylaxis
10
Annual bleed rate (ABR) <1 on prophylaxis vs 30-40 untreated
11
Inhibitor incidence 25-30% lifetime in severe Hemophilia A
12
Renal failure from amyloidosis rare 1-2% long-term
13
Target joint resolution 70% with intensive prophylaxis
14
Morbidity index (WFH score) <10 in 80% early prophylaxis starters
15
Cancer risk elevated 2x from factor exposure impurities historically
16
Employment rate 60% in adults vs 90% general population
17
Neurological sequelae from ICH in 50% neonatal survivors
18
VTE post-surgery 5% despite prophylaxis
19
Hemophilic arthropathy FISH score correlates 90% with pain
20
Survival to 50 years 89% with prophylaxis vs 66% episodic
21
Anaphylaxis to factor concentrates 1-3% high-risk patients
22
Chronic synovitis pain managed 75% with radiosynovectomy
23
Educational attainment similar to peers 85% with treatment access
24
Inhibitor relapse 20% post-ITI success
25
Liver fibrosis reversal post-DAA HCV treatment in 90%
26
Psychosocial burden depression 30% higher untreated
27
Gene therapy durability 3-5 years 70% sustained expression
28
Orthopedic complications post-total knee 10% infection
29
Economic burden $300,000/year per severe patient untreated
Interpretation
Outcomes and Complications Interpretation
Hemophilia treatment has gifted patients decades of life, yet the legacy of past tragedies and the relentless grind of managing a complex, chronic condition mean that survival is a hard-won, multifaceted battle far beyond simply stopping the bleed.
05 · Category
Treatment29 stats
01
Prophylactic factor replacement started at 1-2 years reduces bleeds by 90%
02
Recombinant factor VIII half-life 8-12 hours, dosed 20-40 IU/kg 3x/week
03
Emicizumab prophylaxis reduces bleeds by 87% in inhibitor patients
04
Bypassing agents like rFVIIa control 90% acute bleeds in inhibitors
05
Gene therapy with AAV5-hFVIII achieves 30-70% factor expression in 80% patients
06
Desmopressin (DDAVP) boosts factor VIII 2-6 fold in 70% mild Hemophilia A
07
Immune tolerance induction (ITI) eradicates inhibitors in 60-80% Hemophilia A
08
Tranexamic acid reduces dental bleed risk by 50% adjunctively
09
Extended half-life FVIII products reduce infusions by 50%
10
Hemophilia treatment centers improve outcomes in 95% compliance patients
11
Fitusiran RNAi therapy reduces bleeds by 90% monthly dosing
12
rFIX-Fc fusion protein prophylaxis dosing every 7-14 days effective
13
Radio-synovectomy controls target joints in 80% recurrent bleeders
14
VTE risk with factor concentrates is <1% with prophylaxis
15
AAV9-hFIX gene therapy sustains 40% factor IX for 5+ years
16
Continuous infusion of factor saves 30% product usage
17
EHL factor IX reduces annual factor consumption by 40%
18
ITI success higher with high-dose daily FVIII (200 IU/kg/day) at 70%
19
SERPIN PCT3003 topical prevents minor bleeds in 85%
20
Joint aspiration reduces pain in 90% acute hemarthrosis
21
Concizumab subcutaneous prophylaxis cuts bleeds 80%
22
Liver-directed AAV corrects phenotype in 90% low-dose trials
23
Fibrinogen concentrates for afibrinogenemia analogs 95% hemostasis
24
Home treatment programs reduce ER visits by 75%
25
rFVIII-SingleChain stable for 90% bleed control mild-moderate
26
Physical therapy improves joint function 60% post-bleed
27
Marstacimab Factor XIa inhibitor reduces bleeds 70%
28
Orthopedic surgery success 95% with adequate factor cover
29
Bispecific antibodies like emicizumab mimic factor VIII 96% efficacy
Interpretation
Treatment Interpretation
From injecting factor as toddlers to silencing genes as adults, modern hemophilia care is less about simply surviving bleeds and more about artfully hijacking the body's own systems to build a durable, and nearly normal, life from a clever cocktail of prophylaxis, innovation, and stubborn biological persuasion.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Isabelle Moreau. (2026, February 13). Hemophilia Statistics. Gitnux. https://gitnux.org/hemophilia-statistics
MLA
Isabelle Moreau. "Hemophilia Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/hemophilia-statistics.
Chicago
Isabelle Moreau. 2026. "Hemophilia Statistics." Gitnux. https://gitnux.org/hemophilia-statistics.
Sources & references
18 datasets cited across this report · attribution is report-level